Cardiac Arrhythmia Treatment Systems with Advanced Energy Harvesting and AI-Driven Pacing

Next-generation cardiac arrhythmia treatment systems integrating bio-harvested energy sources, neural networks, swarm intelligence algorithms, and real-time feedback loops to revolutionize cardiac pacing and resynchronization therapy.

The original patent addresses the need for improved cardiac arrhythmia treatment devices and delivery methods. However, these systems rely on traditional energy sources and lack advanced analytics and real-time optimization capabilities. The new inventive concept solves these limitations by introducing cutting-edge technologies to create more efficient, effective, and patient-centric treatment solutions.

The inventive concept comprises a family of cardiac arrhythmia treatment systems that integrate advanced energy harvesting, artificial intelligence, and real-time feedback loops. The systems include leadless pacemakers powered by bio-harvested energy sources, neural network-driven cardiac resynchronization therapy, and pulse generators implanted in the rib cage with sensors to monitor cardiac activity. These systems leverage swarm intelligence algorithms and cloud-based databases to optimize pacing protocols and store patient data. The real-time feedback loops enable continuous adjustment of pacing parameters based on patient response.

The new claims introduce novel combinations of bio-harvested energy sources, neural networks, swarm intelligence algorithms, and real-time feedback loops, which are not obvious from the original patent. These advancements enable more efficient, effective, and patient-centric cardiac arrhythmia treatment solutions.

Alternative embodiments may include implantable cardioverter defibrillators with rechargeable batteries, subcutaneously implantable pacemakers with advanced sensors, or external pacemakers with wearable energy harvesting devices. Variations may involve different AI algorithms, energy harvesting technologies, or communication protocols with remote monitoring systems.

The inventive concept has significant commercial potential in the cardiac arrhythmia treatment market, which is expected to grow substantially in the coming years. The technology can be targeted towards medical device manufacturers, hospitals, and clinics, as well as patients seeking more advanced and effective treatment options.